Cullen/Frost Bankers, Inc. Tg Therapeutics, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $7.02 Billion
- Q1 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 51 shares of TGTX stock, worth $1,921. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51Holding current value
$1,921% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TGTX
# of Institutions
379Shares Held
85.5MCall Options Held
3.78MPut Options Held
3M-
Vanguard Group Inc Valley Forge, PA15.6MShares$588 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$429 Million0.0% of portfolio
-
State Street Corp Boston, MA9.2MShares$347 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA3.19MShares$120 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT2.68MShares$101 Million5.62% of portfolio
About TG THERAPEUTICS, INC.
- Ticker TGTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 145,274,000
- Market Cap $5.47B
- Description
- TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...